Skip to main content

The role of iron in tumour cell proliferation

Clinical and Translational Oncology volume 13, pages 71–76 (2011)Cite this article

Abstract

Iron has a pivotal role in homeostasis due to its participation in virtually all of the body’s oxidationreduction processes. However, iron can also be considered a double-edged weapon, as its excess may lead to an increased risk of developing cancer, presumably by the generation of reactive oxygen species, and its role as substrate to enzymes that participate in cell proliferation. Thus, iron might as well be considered a cofactor in tumour cell proliferation. In certain pathological conditions, such as haemochromatosis, hepatitis B and C virus infection, asbestosis and endometriosis, iron overload may increase the risk of cancer. By contrast, iron depletion could be considered a useful adjunct in antitumour therapy. This paper reviews the current scientific evidence behind iron’s role as a protumoral agent, and the potential benefit of a state of iron depletion in patients with cancer.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Zacharski LR, Ornstein DL, Woloshin S et al (2000) Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 140:98–104

    PubMed  Article  CAS  Google Scholar 

  2. Thauer RK, Jungermann K, Decker K (1977) Energy conservation in chemotrophic anaerobic bacteria. Bacteriol Rev 41:100–180

    PubMed  CAS  Google Scholar 

  3. Toyokuni S (2009) Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 100:9–16

    PubMed  Article  CAS  Google Scholar 

  4. Crosby WH (1991) A history of phlebotomy therapy for hemochromatosis. Am J Med Sci 301:28–31

    PubMed  Article  CAS  Google Scholar 

  5. Cappellini MD (2005) Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol 18:289–298

    PubMed  Article  CAS  Google Scholar 

  6. Darnell G, Richardson DR (1999) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 94:781–792

    PubMed  CAS  Google Scholar 

  7. Gao J, Lovejoy D, Richardson DR (1999) Effect of iron chelators with potent anti-proliferative activity on the expression of molecules involved in cell cycle progression and growth. Redox Rep 4:311–312

    PubMed  Article  CAS  Google Scholar 

  8. Kwok JC, Richardson DR (2002) The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol 42:65–78

    PubMed  Article  Google Scholar 

  9. Andrews NC, Bridges KR (1998) Disorders of iron metabolism and sideroblastic anemia. In: Nathan DG, Orkin SH (eds) Hematology of infancy and childhood, 5th Edn. WB Saunders, Philadelphia, p 423–429

    Google Scholar 

  10. Hentze MW, Muckenthaler MU, Galy B et al (2010) Two to tango: regulation of Mammalian iron metabolism. Cell 142:24–38

    PubMed  Article  CAS  Google Scholar 

  11. Frazer DM, Anderson GJ (2003) The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cells Mol Dis 30:288–297

    PubMed  Article  CAS  Google Scholar 

  12. Wulfert M, Kupper AC, Tapprich C et al (2008) Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol 36:577–586

    PubMed  Article  CAS  Google Scholar 

  13. Klausner RD, Rouault TA, Harford JB (1993) Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 72:19–28

    PubMed  Article  CAS  Google Scholar 

  14. Casey JL, Hentze MW, Koeller DM et al (1988) Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. Science 240:924–928

    PubMed  Article  CAS  Google Scholar 

  15. Leibold EA, Munro HN (1988) Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5′ untranslated region of ferritin heavy- and light-subunit mRNAs. Proc Natl Acad Sci U S A 85:2171–2175

    PubMed  Article  CAS  Google Scholar 

  16. Hentze MW, Kuhn LC (1996) Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci U S A 93:8175–8182

    PubMed  Article  CAS  Google Scholar 

  17. Merkofer M, Kissner R, Hider RC et al (2006) Fenton chemistry and iron chelation under physiologically relevant conditions: electrochemistry and kinetics. Chem Res Toxicol 19:1263–1269

    PubMed  Article  CAS  Google Scholar 

  18. Barbouti A, Doulias PT, Zhu BZ et al (2001) Intracellular iron, but not copper, plays a critical role in hydrogen peroxide-induced DNA damage. Free Radic Biol Med 31:490–498

    PubMed  Article  CAS  Google Scholar 

  19. Pantopoulos K (2004) Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci 1012:1–13

    PubMed  Article  CAS  Google Scholar 

  20. McCord JM (2004) Iron, free radicals, and oxidative injury. J Nutr 134:3171S–3172S

    PubMed  CAS  Google Scholar 

  21. Dizdaroglu M, Jaruga P, Birincioglu M et al (2002) Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med 32:1102–1115

    PubMed  Article  CAS  Google Scholar 

  22. Galaris D, Skiada V, Barbouti A (2008) Redox signaling and cancer: the role of “labile” iron. Cancer Lett 266:21–2

    PubMed  Article  CAS  Google Scholar 

  23. Koptyra M, Falinski R, Nowicki MO et al (2006) BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108:319–327

    PubMed  Article  CAS  Google Scholar 

  24. Kovacevic Z, Richardson DR (2006) The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 27:2355–2366

    PubMed  Article  CAS  Google Scholar 

  25. Sanz G, Nomdedeu B, Such E et al (2008) Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts) 112

  26. Mainous AG 3rd, Gill JM, Carek PJ (2004) Elevated serum transferrin saturation and mortality. Ann Fam Med 2:133–138

    PubMed  Article  Google Scholar 

  27. Knekt P, Reunanen A, Takkunen H et al (1994) Body iron stores and risk of cancer. Int J Cancer 56:379–382

    PubMed  Article  CAS  Google Scholar 

  28. Mainous AG 3rd, Gill JM, Everett CJ (2005) Transferrin saturation, dietary iron intake, and risk of cancer. Ann Fam Med 3:131–137

    PubMed  Article  Google Scholar 

  29. Yoshinari K, Yuasa K, Iga F et al (1989) A growthpromoting factor for human myeloid leukemia cells from horse serum identified as horse serum transferrin. Biochim Biophys Acta 1010:28–34

    PubMed  Article  CAS  Google Scholar 

  30. Sekyere EO, Dunn LL, Rahmanto YS et al (2006) Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. Blood 107:2599–2601

    PubMed  Article  CAS  Google Scholar 

  31. Richardson DR, Baker E (1990) The uptake of iron and transferrin by the human malignant melanoma cell. Biochim Biophys Acta 1053:1–12

    PubMed  Article  CAS  Google Scholar 

  32. Sekyere E, Richardson DR (2000) The membrane-bound transferrin homologue melanotransferrin: roles other than iron transport? FEBS Lett 483:11–16

    PubMed  Article  CAS  Google Scholar 

  33. Kawabata H, Germain RS, Vuong PT et al (2000) Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo. J Biol Chem 275:16618–16625

    PubMed  Article  CAS  Google Scholar 

  34. Macedo MF, de Sousa M (2008) Transferrin and the transferrin receptor: of magic bullets and other concerns. Inflamm Allergy Drug Targets 7:41–52

    PubMed  Article  CAS  Google Scholar 

  35. Das Gupta A, Patil J, Shah VI (1996) Transferrin receptor expression by blast cells in acute lymphoblastic leukemia correlates with white cell count & immunophenotype. Indian J Med Res 104:226–233

    PubMed  Google Scholar 

  36. Goding JW, Burns GF (1981) Monoclonal antibody OKT-9 recognizes the receptor for transferrin on human acute lymphocytic leukemia cells. J Immunol 127:1256–1258

    PubMed  CAS  Google Scholar 

  37. Nouri AM, Smith S, Oliver TR et al (1998) Comparative expression of major histocompatibility complex (MHC) antigens on CD5+ and CD5-B cells in patients with chronic lymphocytic leukaemia (CLL). Eur J Cancer 34:1618–1622

    PubMed  Article  CAS  Google Scholar 

  38. Smilevska T, Stamatopoulos K, Samara M et al (2006) Transferrin receptor-1 and 2 expression in chronic lymphocytic leukemia. Leuk Res 30:183–189

    PubMed  Article  CAS  Google Scholar 

  39. Tei I, Makino Y, Sakagami H et al (1982) Decrease of transferrin receptor during mouse myeloid leukemia (M1) cell differentiation. Biochem Biophys Res Commun 107:1419–1424

    PubMed  Article  CAS  Google Scholar 

  40. Taetle R, Rhyner K, Castagnola J et al (1985) Role of transferrin, Fe, and transferrin receptors in myeloid leukemia cell growth. Studies with an antitransferrin receptor monoclonal antibody. J Clin Invest 75:1061–1067

    PubMed  Article  CAS  Google Scholar 

  41. Lepelletier Y, Camara-Clayette V, Jin H et al (2007) Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res 67:1145–1154

    PubMed  Article  CAS  Google Scholar 

  42. Callens C, Moura IC, Lepelletier Y et al (2008) Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia 22:42–48

    PubMed  Article  CAS  Google Scholar 

  43. Habeshaw JA, Lister TA, Stansfeld AG et al (1983) Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet 1:498–501

    PubMed  Article  CAS  Google Scholar 

  44. Nejmeddine F, Raphael M, Martin A et al (1999) 67Ga scintigraphy in B-cell non-Hodgkin’s lymphoma: correlation of 67Ga uptake with histology and transferrin receptor expression. J Nucl Med 40:40–45

    PubMed  CAS  Google Scholar 

  45. Deiss A (1983) Iron metabolism in reticuloendothelial cells. Semin Hematol 20:81–90

    PubMed  CAS  Google Scholar 

  46. Ruggeri G, Iacobello C, Albertini A et al (1984) Studies of human ferritin in tissues and body fluids. Elsevier, Amsterdam

    Google Scholar 

  47. Harrison PM, Arosio P (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275:161–203

    PubMed  Article  Google Scholar 

  48. Broxmeyer HE, Gentile P, Bognacki J et al (1983) Lactoferrin, transferrin and acidic isoferritins: regulatory molecules with potential therapeutic value in leukemia. Blood Cells 9:83–105

    PubMed  CAS  Google Scholar 

  49. de Sousa M, Smithyman A, Tan C (1978) Suggested models of ecotaxopathy in lymphoreticular malignancy. A role for iron-binding proteins in the control of lymphoid cell migration. Am J Pathol 90:497–520

    PubMed  Google Scholar 

  50. Hancock BW, Bruce L, May K et al (1979) Ferritin, a sensitizing substance in the leucocyte migration inhibition test in patients with malignant lymphoma. Br J Haematol 43:223–233

    PubMed  Article  CAS  Google Scholar 

  51. Aulbert E, Schmidt CG (1985) Ferritin: a tumor marker in myeloid leukemia. Cancer Detect Prev 8:297–302

    PubMed  CAS  Google Scholar 

  52. Lang JM, Eber M, Methlin G et al (1982) Serum ferritin during the course of chronic myeloid leukemia. Increase of serum ferritin as a marker of dyserythropoiesis. Acta Haematol 67:145–149

    PubMed  Article  CAS  Google Scholar 

  53. Richardson DR, Ponka P (1994) The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med 124:660–671

    PubMed  CAS  Google Scholar 

  54. Gray CP, Franco AV, Arosio P et al (2001) Immunosuppressive effects of melanoma-derived heavy-chain ferritin are dependent on stimulation of IL-10 production. Int J Cancer 92:843–850

    PubMed  Article  CAS  Google Scholar 

  55. Kalinowski DS, Richardson DR (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57:547–583

    PubMed  Article  CAS  Google Scholar 

  56. Epsztejn S, Glickstein H, Picard V et al (1999) H-ferritin subunit overexpression in erythroid cells reduces the oxidative stress response and induces multidrug resistance properties. Blood 94:3593–3603

    PubMed  CAS  Google Scholar 

  57. Thelander L, Reichard P (1979) Reduction of ribonucleotides. Annu Rev Biochem 48:133–158

    PubMed  Article  CAS  Google Scholar 

  58. Renton FJ, Jeitner TM (1996) Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators. Biochem Pharmacol 51:1553–1561

    PubMed  Article  CAS  Google Scholar 

  59. Yu Y, Kovacevic Z, Richardson DR (2007) Tuning cell cycle regulation with an iron key. Cell Cycle 6:1982–1994

    PubMed  Article  CAS  Google Scholar 

  60. Leitch HA, Wong DH, Leger CS (2007) Improved survival in myelodysplastic syndromes patients receiving iron chelation therapy. Leuk Res 31[Suppl 1]:S15

    Article  Google Scholar 

  61. Donfrancesco A, Deb G, Dominici C et al (1990) Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 50:4929–4930

    PubMed  CAS  Google Scholar 

  62. Estrov Z, Tawa A, Wang XH et al (1987) In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 69:757–761

    PubMed  CAS  Google Scholar 

  63. Kaplinsky C, Estrov Z, Freedman MH et al (1987) Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells. Leukemia 1:437–441

    PubMed  CAS  Google Scholar 

  64. Whitnall M, Howard J, Ponka P et al (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 103:14901–14906

    PubMed  Article  CAS  Google Scholar 

  65. Gojo I, Tidwell ML, Greer J et al (2007) Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res 31:1165–1173

    PubMed  Article  CAS  Google Scholar 

  66. Richardson DR, Milnes K (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 89:3025–3038

    PubMed  CAS  Google Scholar 

  67. Chantrel-Groussard K, Gaboriau F, Pasdeloup N et al (2006) The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox. Eur J Pharmacol 541:129–137

    PubMed  Article  CAS  Google Scholar 

  68. Lescoat G, Chantrel-Groussard K, Pasdeloup N et al (2007) Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell Prolif 40:755–767

    PubMed  Article  CAS  Google Scholar 

  69. Schwartz RN (2007) Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm 64:S5–13; quiz S28–30

    PubMed  Article  CAS  Google Scholar 

  70. Weiss G, Wachter H, Fuchs D (1995) Linkage of cell-mediated immunity to iron metabolism. Immunol Today 16:495–500

    PubMed  Article  CAS  Google Scholar 

  71. Glaspy J, Crawford J, Vansteenkiste J et al (2010) Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 102:301–315

    PubMed  Article  CAS  Google Scholar 

  72. Farrell F, Lee A (2004) The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9[Suppl 5]:18–30

    Article  Google Scholar 

  73. Sytkowski AJ (2007) Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci STKE 2007:pe38

    PubMed  Article  Google Scholar 

  74. Sulkowska M, Wincewicz A, Chabowska A et al (2006) To give or not to give recombinant EPO to anemia endangered cancer patients. Prague Med Rep 107:281–289

    PubMed  CAS  Google Scholar 

  75. Sinclair AM, Coxon A, McCaffery I et al (2010) Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 115:4264–4272

    PubMed  Article  CAS  Google Scholar 

  76. Swift S, Ellison AR, Kassner P et al (2010) Absence of functional EpoR expression in human tumor cell lines. Blood 115:4254–4263

    PubMed  Article  CAS  Google Scholar 

  77. Beguin Y (2005) Intravenous iron and recombinant human erythropoietin in cancer patients. J Clin Oncol 23:651–652; author reply 652–653

    PubMed  Article  Google Scholar 

  78. Osterborg A, Steegmann JL, Hellmann A et al (2007) Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin’s lymphoma receiving combination chemotherapy. Br J Haematol 136:736–744

    PubMed  Article  Google Scholar 

  79. de Witte T (2008) The role of iron in patients after bone marrow transplantation. Blood Rev 22[Suppl 2]:S22–28

    PubMed  Google Scholar 

  80. Pullarkat V, Blanchard S, Tegtmeier B et al (2008) Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 42:799–805

    PubMed  Article  CAS  Google Scholar 

  81. Chotsampancharoen T, Gan K, Kasow KA et al (2009) Iron overload in survivors of childhood leukemia after allogeneic hematopoietic stem cell transplantation. Pediatr Transplant 13:348–352

    PubMed  Article  CAS  Google Scholar 

  82. Neufeld EJ (2006) Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 107:3436–3441

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Hematology, Hospital Universitario de La Princesa, C/Diego de León, 62, ES-28006, Madrid, Spain

    Juan Luis Steegmann-Olmedillas

Authors
  1. Juan Luis Steegmann-Olmedillas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juan Luis Steegmann-Olmedillas.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Steegmann-Olmedillas, J.L. The role of iron in tumour cell proliferation. Clin Transl Oncol 13, 71–76 (2011). https://doi.org/10.1007/s12094-011-0621-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-011-0621-1

Keywords

  • Carcinogenesis
  • Iron overload
  • Iron metabolism
  • Iron-chelating therapy